Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xanodyne Pharmaceuticals, Ferring To Co-promote Zipsor
Zipsor, a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of mild to moderate acute pain in adults, received FDA approval in June 2009. As per the agreement,
Zipsor, a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of mild to moderate acute pain in adults, received FDA approval in June 2009. As per the agreement,
ACG North America will be headquartered in South Plainfield, New Jersey with offices in Indiana, South Carolina, and Utah in the US; Montreal and Vancouver in Canada; and
Hamamatsu said that the uCELL (micro cell) offers a cost-effective way for biotechnology companies, research institutes, and clinical research organizations to introduce advanced FDSS (Functional Drug Screening System)
The randomised, double-blind, placebo-controlled study is expected to investigate the safety, tolerability and pharmacokinetic profile of NRM8499 in a group of up to 84 young and elderly healthy
Galantamine is a drug for Alzheimer’s disease and chemically known as galantamine hydrobromide (hereinafter called galantamine). Following the development of Galantamine by Janssen Pharmaceutica, for the treatment of
AmVac said that the novel technology, used for producing vaccines and has been developed at the research site in Martinsried near Munich, Germany, is completely covered by the
Simcere Pharmaceutical said that as a result of the investigation conducted by the local food and drug regulatory authority and local police department the SFDA found that the
The combined company is expected to have multiple proprietary RNAi drug discovery platforms with the capability to deliver RNAi-based therapeutics via systemic, local and oral administration. In addition,
FY 2009 gross profit increased 96% to $39m, compared to $19.9m for FY2008 and gross margin increased 1,470 basis points to 73.2%. Operating expenses were $23.9m, up 97.7%
KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris, in the US, Canada and Mexico. A randomised, double-blind Phase 3 trial investigating Perifosine in combination with capecitabine (Xeloda)